Radiopharm's 15min chart triggers Bollinger Bands Narrowing, KDJ Death Cross formation.

Based on the 15-minute chart for Radiopharm, the narrowing of Bollinger Bands and the KDJ Death Cross observed on August 5, 2025 at 13:15 indicates a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further declines in the stock price.

Gossamer Bio, Inc. (GOSS), a clinical-stage biopharmaceutical company, recently reported its second quarter 2025 financial results and provided updates on its lead drug candidate, seralutinib. The company completed enrollment of 390 patients in its Phase 3 PROSERA study for the treatment of pulmonary arterial hypertension (PAH), with topline results expected in February 2026. The study's primary endpoint is the change in six-minute walk distance at week 24.

Financial highlights for Q2 2025 include $212.9 million in cash and equivalents, expected to fund operations into 2027. The company reported Q2 revenue of $11.5 million, with a net loss of $38.3 million ($0.17 per share). The company is also preparing to launch the Phase 3 SERANATA study for pulmonary hypertension associated with interstitial lung disease (PH-ILD) in Q4 2025, targeting approximately 480 patients.

Gossamer Bio is a late-stage biopharmaceutical company developing seralutinib for the treatment of PAH and PH-ILD. The company's lead candidate, seralutinib, is advancing with the PROSERA Phase 3 trial in PAH, with topline data expected in Q4 2025. The company has also received Orphan Drug Designation in Japan for PAH treatment and plans to initiate a registrational Phase 3 trial for PH-ILD in H2 2025.

The company's stock price has been volatile, with a narrowing of Bollinger Bands and a KDJ Death Cross observed on August 5, 2025 at 13:15, indicating a decrease in the magnitude of stock price fluctuations and a shift in momentum towards the downside, potentially leading to further declines in the stock price.

Gossamer Bio is a promising biopharmaceutical company with a strong pipeline of drug candidates targeting complex conditions. However, investors should closely monitor the company's financial results and clinical trial data to make informed investment decisions.

References:
[1] https://www.stocktitan.net/news/GOSS/
[2] https://www.stocktitan.net/news/GOSS/